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Microtubule-targeting agents can sensitize cancer 
cells to ionizing radiation by an interphase-based 
mechanism
Daniel Markowitz1,2
grace ha2
rosamaria ruggieri1,2
Marc symons1,2
1hofstra northwell school of 
Medicine, hempstead, 2Karches 
center for Oncology research, 
Feinstein institute for Medical 
research, Manhasset, nY, Usa
Background: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed 
to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging 
agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to 
DNA damage. In contrast, recent studies suggest that MTAs synergize with IR by interfering 
with the trafficking of DNA damage response (DDR) proteins during interphase. These studies, 
however, have yet to demonstrate the functional consequences of interfering with interphase 
microtubules in the presence of IR. To address this, we combined IR with an established MTA, 
mebendazole (MBZ), to treat glioma cells exclusively during interphase.
Materials and methods: To test whether MTAs can sensitize interphase cells to IR, we 
treated GL261 and GBM14 glioma cells with MBZ during 3–9 hours post IR (when the mitotic 
index was 0%). Cell viability was measured using a WST-1 assay, and radiosensitization was 
quantified using the dose enhancement factor (DEF). The effect of MBZ on the DDR was 
studied via Western blot analysis of H2AX phosphorylation. To examine the effects of MTAs on 
intracellular transport of DDR proteins, Nbs1 and Chk2, cytoplasmic and nuclear fractionation 
studies were conducted following treatment of glioma cells with MBZ.
Results: Treatment with MBZ sensitized interphase cells to the effects of IR, with a maximal 
DEF of 1.34 in GL261 cells and 1.69 in GBM14 cells. Treatment of interphase cells with MBZ 
led to more sustained γH2AX levels post IR, indicating a delay in the DDR. Exposure of glioma 
cells to MBZ resulted in a dose-dependent sequestration of Chk2 and Nbs1 in the cytoplasm.
Conclusion: This study demonstrates that MBZ can sensitize cancer cells to IR independently 
of the induction of mitotic arrest. In addition, evidence is provided supporting the hypothesis 
that MTA-induced radiosensitization is mediated by inhibiting DDR protein accumulation into 
the nucleus.
Keywords: microtubules, mebendazole, ionizing radiation, radiosensitization, interphase, 
DNA damage response
Introduction
Microtubule-targeting agents (MTAs) have been used for a long time against a wide 
range of malignancies. It is generally believed that MTAs kill cancer cells by causing 
cell cycle arrest in M-phase, followed by activation of apoptotic pathways and cell 
death.1–4 Many studies have used this rationale to explain the potent radiosensitization 
effects exerted by MTAs,5,6 ie, by inducing mitotic arrest, MTAs increase the proportion 
of tumor cells in a phase of the cell cycle that is very susceptible to DNA damage.7,8 
Currently, chemoradiotherapy regimens including MTAs have been proven effective for 
the treatment of breast cancer, esophageal cancer and a variety of other neoplasms.9,10
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Support for a mitosis-based mechanism for the therapeu-
tic effects of MTAs has been derived from the characteristic 
side effects of these drugs, which include hair loss, neutro-
penia and gastrointestinal upset. These deleterious effects 
demonstrate the profound sensitivity of rapidly dividing 
tissues to MTAs. However, the action of MTAs on mitotic 
cells fails to explain their clinical efficacy against many 
slow-growing solid tumors with exceptionally low mitotic 
indices.11 Most human tumors have a doubling time of 
30–60 days or longer, making it unlikely that mitotic arrest 
serves as a critical mechanism of MTA-induced therapeutic 
benefit.12 A prime example of this “proliferation rate paradox” 
is the significant activity of MTAs against adenocarcinoma 
of the prostate, a highly indolent cancer.13,14 Thus, a number 
of interphase-based mechanisms for the efficacy of MTAs 
in cancer therapy have been proposed, although not without 
controversy.15,16
A recent study has shown that the MTAs, vincristine 
(VCR) and paclitaxel, can delay DNA damage repair.17 These 
MTAs were also shown to interfere with the trafficking of 
DNA damage response (DDR) proteins, including ATM, 
ATR and p53, from the cytosol to the nucleus, strongly 
suggesting that MTAs can sensitize cells to radiation by 
blocking microtubule-based transport of DDR proteins into 
the nucleus during interphase.
It is challenging to physically separate mitotic from inter-
phase cells in the presence of an MTA, as this results in a 
steady accumulation of new mitotic cells as long as the MTA 
is present. Thus, the question remains as to what extent the 
role of MTAs in radiosensitization is caused by interference 
with microtubule-facilitated nuclear import. To address this 
question, we took advantage of the fact that ionizing radiation 
(IR) treatment induces G2–M cell cycle arrest, thereby tran-
siently eliminating the mitotic cell population and strongly 
enriching for interphase cells. Using glioblastoma cells and 
the MTA, mebendazole (MBZ), as a model system, we show 
that the effect of MBZ in interphase is responsible for the 
majority of the radiosensitization effect of this MTA.
Materials and methods
cell lines and reagents
GL261 (glioma) cells were obtained from the National 
Cancer Institute (Frederick, MD, USA). Cells were cultured 
in macrophage serum-free medium (Thermo Fisher Scientific, 
Waltham, MA, USA) containing 10% fetal bovine serum, 1% 
penicillin/streptomycin and 1 mM l-glutamine. GBM14 cells 
have been described previously,18 and they were obtained 
by Dr J Sarkaria at Mayo Clinic (Rochester, MN, USA) 
and cultured in StemPro media (Thermo Fisher Scientific), 
as directed by the manufacturer.
Drug treatment
For each experiment, GL261 and GBM14 cells were cultured 
without drug or treated with MBZ (Sigma-Aldrich Co., 
St Louis, MO, USA). MBZ stocks were prepared by dissolving 
the drug in dimethyl sulfoxide (DMSO; Sigma-Aldrich Co.). 
About 24 hours after plating, glioma cells were treated with 
MBZ, while control cells were treated with 0.01% DMSO.
irradiation procedure
For all experiments requiring radiation, cells were irradiated 
using a biological irradiator (RS2000; Rad Source Technolo-
gies, Buford, GA, USA).
antibodies
Phospho-MPM2 was obtained from EMD Millipore (Billerica, 
MA, USA), and γH2AX, H2AX, Chk2, Nbs1 and GAPDH 
were purchased from Cell Signaling (Danvers, MA, USA).
Immunofluorescence
GL261 cells were seeded at a density of 30,000 cells/well 
in 24-well plates containing cover slips coated with laminin 
(Sigma-Aldrich Co.). The following day, cells were exposed 
to 6 Gy of IR. At designated time points post IR, cells were 
washed in PBS and fixed in 4% formaldehyde in PBS at room 
temperature. Once the cells were fixed, immunofluorescence 
was performed using an MPM2 antibody (EMD Millipore) 
and counterstained with 4,6-Diamidino-2-phenylindole, 
dihydrochloride (DAPI). For each condition, a total of 10 
fluorescence micrograph images were taken with a Zeiss 
Axiovert 200M inverted microscope (Thornwood, NY, USA), 
running on Axiovision software. For each image field, the 
total number of cells and the number of MPM2-positive cells 
were quantified. The mitotic index was calculated at each time 
point using the number of MPM2-positive cells as a percent-
age of the total number of cells counted in all 10 fields.
cell viability assays
GL261 cells were seeded in 96-well plates at a density of 
1,000 cells/well. GBM14 cells were seeded at a density of 
10,000 cells/well. About 24 hours after seeding, cells were 
treated with 25–150 nM MBZ and irradiated with 3, 6 or 9 Gy. 
Drug treatment was applied for a 6-hour time window begin-
ning either 6 hours pre IR or 3 hours post IR. Following the 
6-hour window, the drug was washed out and replaced with 
fresh medium. Control cells were either left nonirradiated or 
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irradiated with 3, 6 or 9 Gy of IR. Cell viability was examined 
72 hours post IR using a WST-1 cell viability assay (Abcam, 
Cambridge, MA, USA) at an absorbance of 450 nm. For any 
given radiation dose–response, data were normalized by the 
fraction of viable cells treated with a given dose of drug 
in the absence of radiation. The radiosensitizing effect of 
MBZ and VCR was quantified using the dose enhancement 
factor (DEF) at the point of 50% (DEF
50
) cell viability. The 
DEF was calculated for each MBZ concentration using the 
following formula: (surviving fraction with radiation alone)/
(surviving fraction with radiation + MBZ).
assessment of the DDr
GL261 cells were seeded at a density of 800,000 cells/well 
in 6-cm dishes. About 24 hours after seeding, cells were 
irradiated with 6 Gy of IR, followed by treatment with 
150 nM MBZ during 3–9 hours post IR. Control cells were 
either left nonirradiated or irradiated with 6 Gy. All cells 
were harvested in lysis buffer at 0.5, 3, 6 and 9 hours post 
IR. The lysis buffer was composed of 50 mM Tris–HCl 
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 10% Nonidet P-40, 
1× protease inhibitor (Thermo Fisher Scientific), phosphatase 
inhibitor (Hoffman-La Roche Ltd., Basel, Switzerland) and 
0.4 U/mL Benzonase (EMD Millipore). For each condition, 
60 µg of cell lysate was diluted in 1× NuPAGE Sample 
Reducing Agent (Thermo Fisher Scientific) and 1× NuPAGE 
LDS Sample Buffer (Thermo Fisher Scientific). All samples 
were loaded onto a NuPAGE, 4%–12% Bis-Tris Protein Gel 
(Thermo Fisher Scientific) for Western blot analysis. Histone 
H2AX and γH2AX were detected by Western blot using 
anti-histone H2AX or anti-γ-H2AX (Ser139) monoclonal 
antibodies (Cell Signaling).
nuclear and cytoplasmic fractionation
GL261 cells were seeded at a density of 500,000 cells in 
6-cm dishes. The following day, cells were treated with 3 Gy. 
MBZ treatment (25–250 nM) was performed for a 6-hour 
time window beginning 3 hours post IR. Irradiated control 
cells were treated with 3 Gy followed by 0.01% DMSO in 
medium during the same time period. Nonirradiated control 
cells were treated with 0.01% DMSO in medium for a total 
of 6 hours. After the 6-hour period of MBZ treatment, cells 
were harvested for protein analysis in cytoplasmic (C) and 
nuclear (N) fractions. The C and N fractions were collected 
according to the protocol of the NE-PER Nuclear and Cyto-
plasmic Extraction Reagents Kit (Thermo Fisher Scientific). 
For each sample, 20% of the final volume of the C or N frac-
tions was diluted in 1× NuPAGE Sample Reducing Agent 
and 1× NuPAGE LDS Sample Buffer. All samples were 
loaded onto a NuPAGE, 4%–12% Bis-Tris Protein Gel for 
Western blot analysis. Blots were incubated in antibodies: 
Nbs1, Chk2, GAPDH and H2AX monoclonal antibodies (all 
from Cell signaling). Cytoplasmic and nuclear fractions were 
normalized by GAPDH and H2AX levels, respectively. The 
percentage of cytoplasmic retention of DDR proteins was 
calculated by the following formula: [C/(C + N)] × 100%.
statistical analysis
All analyses were performed using Graphpad Prism 7 
software. Radiosensitization experiments were analyzed 
using the two-way ANOVA method to compare the mean 
cell viability between treatment groups. The interaction 
between the MBZ treatment group and radiation dose was 
also examined. One-way ANOVA was used to compare the 
concentration of a drug that gives half-maximal response 
(EC
50
) values for each effect as outlined in Table 1. If a sig-
nificant difference between means was found by ANOVA, 
then multiple comparisons between treatment groups were 
conducted. The Tukey–Kramer method was used to adjust for 
multiple comparisons. Studies examining the effect of MBZ 
on intracellular transport of DDR proteins were analyzed with 
unpaired two-tailed Student’s t-test for direct comparisons 
of means. The same method was used to compare means in 
the analysis of H2AX phosphorylation following exposure 
to IR. For all studies, results were considered statistically 
significant for values of P,0.05.
Results
ir transiently eliminates the mitotic 
cell population
To select for a population composed entirely of interphase 
cells, we took advantage of the fact that IR treatment induces 
G2–M cell cycle arrest and transiently eliminates the mitotic 
Table 1 DeF50 for MBZ-mediated radiosensitization, cytoplasmic 
sequestration of DDr proteins and induction of mitotic arrest
Treatment EC50 (nM) 95% CI
radiosensitization (DeF50) 35 9–50
Nuclear trafficking (Chk2) 31 17–45
Nuclear trafficking (Nbs1) 25 18–32
Mitotic arrest 192* 127–257
Notes: each ec50 value represents the average of three independent experiments 
with the representative 95% ci. DeFs were determined from WsT assays conducted 
in gl261 cells with MBZ treatment during the period of 3–9 hours post ir. The ec50 
of radiosensitization is defined by the half-maximal DEF at 50% cell viability (DEF50). 
Data used to determine the ec50 for induction of mitotic arrest by MBZ were 
obtained previously, also using gl261 cells.23 *P,0.01.
Abbreviations: CI, confidence interval; DDR, DNA damage response; DEF, dose 
enhancement factor; EC50, concentration of a drug that gives half-maximal response; 
IR, ionizing radiation; MBZ, mebendazole.
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cell population. Glioma cells were treated with 6 Gy of IR. 
To monitor the mitotic index, we quantified the proportion 
of MPM2-positive cells by immunofluorescence at several 
time points post IR. MPM2 is an antibody that recognizes 
a phosphorylated serine/threonine epitope found in proteins 
that are phosphorylated at the onset of mitosis.19 MPM2 is 
recognized as a reliable mitotic marker in the literature and 
has been used to assess the mitotic index in cells exposed to 
radiation and a number of chemotherapeutic agents.20–22 The 
baseline mitotic index of the glioma cell population was 3.5% 
and was strongly inhibited during a period of 3–10 hours 
after exposure to 6 Gy of IR. Recovery of the mitotic cell 
population begins after 10 hours post IR and completes by 
24 hours post IR. To confirm that the mitotic index remained 
strongly inhibited even in the presence of MBZ, we applied 
MBZ during 3–9 hours post IR. In the presence of MBZ, 
the mitotic index remained suppressed at 4 hours (mitotic 
index =0.58%), 6 hours (mitotic index =0.12%) and 9 hours 
(mitotic index =0.28%) post IR. Thus, the treatment of GL261 
glioma cells with 6 Gy of IR eliminated the mitotic cell popu-
lation for a time period of ~6 hours (Figure 1).
MTas sensitize interphase cells to ir
In the following experiments, we compared the radiosensitiz-
ing effect of MTAs when applied during different time periods 
with respect to IR, using both murine GL261 cells and primary 
patient-derived GBM14 cells. A simplified schematic of all 
three treatment conditions is shown in Figure 2. To examine 
whether MTAs can sensitize glioma cells to IR, we treated 
GL261 cells with MBZ (Figures 3 and 4) or VCR (Figure 5). 
In order to test, whether MTAs can sensitize interphase cells 
to IR, we treated glioma cells with 25–150 nM MBZ during 
3–9 hours post IR (Figures 3A and 4A). The use of MBZ 
after exposure to IR made it possible to study the impact of 
MBZ independent of its effect on mitotic cells. Cells were 
exposed to MBZ after different doses of IR. After this 6-hour 
time frame, the drug was washed out and replaced with a 
drug-free medium. The radiosensitizing effect of MBZ on 
interphase cells was compared with the effect of MBZ on a 
cell population composed of both interphase and mitotic cells. 
Thus, cells were treated with MBZ for a 6-hour time window 
immediately prior to irradiation, and subsequently the drug 
was either washed out and replaced with drug-free medium 
(Figures 3B and 4B) or left in the original medium until the end 
of the assay, 72 hours post IR (Figures 3C and 4C). Treatment 
with MBZ post IR sensitized GL261 cells to IR with a maximal 
DEF at 50% viability (DEF
50
) of 1.34 (Figure 3D). Treatment 
for a 6-hour time window pre IR, which increased the mitotic 
index to 9.2% from a baseline value of 2.8%,23 sensitized 
glioma cells to IR with a maximal DEF
50
 of 1.2 in GL261 
cells (Figure 3E) and 1.33 in GBM14 cells (Figure 4E). In the 
GL261 cell line, maximal radiosensitization was observed 
when the drug was applied pre IR and left in the medium for 
72 hours, DEF
50
 =1.41 (Figure 3F). In the GBM14 cell line, the 
application of the drug pre IR followed by 72-hour incubation 
sensitized cells to IR with a DEF
50
 =1.60 (Figure 4F). Maximal 
radiosensitization in the GBM14 cell line was achieved when 
MBZ was applied post IR, DEF
50
 =1.69 (Figure 4D). These 
observations show a maximal or near-maximal radiosensitiza-
tion effect of MBZ when applied to cells during interphase.
To investigate whether these findings can be generalized 
to other MTAs, we performed an identical set of experi-
ments in GL261 cells using VCR, an established MTA that 
is frequently used in clinical practice. The radiosensitizing 
effect of VCR was greatest when applied post IR, DEF
50
 =1.53 
(Figure 5A and D). The application of VCR for a 6-hour 
Figure 2 Timing of MBZ application with respect to ir.
Notes: (A) MBZ was applied for a 6-hour time frame beginning 6 hours pre ir 
followed by washout of the drug. During this time period, both mitotic and interphase 
cells were present. (B) MBZ was applied for a 6-hour time frame beginning 3 hours 
post ir followed by washout of the drug. During this time period, the mitotic cell 
population was absent (composed entirely of interphase cells). (C) MBZ was applied 
beginning 6 hour pre ir and left in the medium for the duration of the experiment.
Abbreviations: IR, ionizing radiation; MBZ, mebendazole.
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Figure 1 ir temporarily eliminates the mitotic cell population.
Notes: gl261 cells were exposed to 6 gy of ir, and the proportion of MPM2-
positive cells was quantified by immunofluorescence as described in the 
“Immunofluorescence” section. MPM2 was utilized as a marker of the mitotic index. 
Data are expressed as the average ± seM of three independent experiments.
Abbreviations: IR, ionizing radiation; SEM, standard error of the mean.
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period pre IR radiosensitized GL261 cells with a DEF
50
 of 
1.34 (Figure 5B and E). When VCR was applied pre IR and 
left in the medium for the remaining 72 hours, the magnitude 
of the radiosensitizing effect was quite similar, DEF
50
 =1.30 
(Figure 5C and F). Thus, it appears that the radiosensitizing 
effect of both MBZ and VCR is largely determined by the 
impact of these agents on interphase cells.
MBZ treatment prolongs DDr after 
irradiation
To confirm that MTAs sensitize interphase cells to IR by inter-
fering with the DDR, we examined the level of IR-induced 
phosphorylated H2AX (γH2AX), which is a highly sensitive 
marker of DNA damage.24,25 We exposed glioma cells to 
6 Gy of IR, followed by treatment with 150 nM MBZ during 
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Figure 3 MBZ sensitizes gl261 cells to ir.
Notes: gl261 cells were exposed to 25–150 nM of MBZ in conjunction with 3–9 gy of ir. MBZ treatment was applied at different time points with respect to ir, and cell 
viability was determined by the WST assay as described in the “Cell viability assays” section. All data are expressed as the average ± seM of four independent experiments. 
For each radiation dose–response curve, data were normalized by the fraction of viable cells treated with a given dose of MBZ in the absence of ir. DeFs were determined 
at the point of 50% cell viability. (A) cells were treated with MBZ during 3–9 hours post ir. (B) cells were treated with MBZ for a 6-hour time window immediately prior 
to irradiation. (C) cells were treated with MBZ starting 6 hours prior to irradiation and until 72 hours post ir. P-values were ,0.05 for all treatments points when doses of 
MBZ $50 nM. (D–F) The respective DEFs were calculated as described in the “Cell viability assays” section. *P,0.05, **P,0.01, ***P,0.001.
Abbreviations: DEF, dose enhancement factor; IR, ionizing radiation; MBZ, mebendazole; SEM, standard error of the mean.
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3–9 hours post IR. Cells were harvested at different time 
points post IR, and γH2AX was quantified by Western blot 
analysis. As shown in Figure 6, treatment with MBZ led to 
more sustained γH2AX levels in response to IR, indicat-
ing a delay in the DDR. This finding demonstrated that 
MTAs sensitize interphase cells to IR by interfering with 
the DDR.
MBZ interferes with the trafficking of 
DDr proteins
To investigate whether MTAs synergize with IR by disrupt-
ing intracellular transport of DDR proteins, we performed 
cytoplasmic and nuclear (C/N) fractionation studies with 
glioma cells that had been exposed to IR followed by treat-
ment with MBZ. Similar to the cell viability studies, MBZ was 
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Figure 4 MBZ sensitizes gBM14 cells to ir.
Notes: gBM14 cells were exposed to 50 or 150 nM of MBZ in conjunction with 3–9 gy of ir. MBZ treatment was applied at different time points with respect to ir, and cell 
viability was determined by the WST assay as described in the “Cell viability assays” section. All data are expressed as the average ± seM of three independent experiments. 
For each radiation dose–response curve, data were normalized by the fraction of viable cells treated with a given dose of MBZ in the absence of ir. DeFs were determined 
at the point of 50% cell viability. (A) cells were treated with MBZ during 3–9 hours post ir. (B) cells were treated with MBZ for a 6-hour time window immediately prior 
to irradiation. (C) cells were treated with MBZ starting 6 hours prior to irradiation until 72 hours post ir. (D–F) The respective DeFs were calculated as described in the 
“Cell viability assays” section. **P,0.01, ***P,0.001.
Abbreviations: DEF, dose enhancement factor; IR, ionizing radiation; MBZ, mebendazole; SEM, standard error of the mean.
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applied during 3–9 hours post IR (only when the mitotic cell 
population was absent). Glioma cells were treated with dif-
ferent concentrations of MBZ followed by C/N fractionation. 
Each fraction was analyzed by Western blot. We selected two 
DDR proteins, Chk2 and Nbs1, to serve as potential targets 
of MTA-mediated toxicity. Chk2 is a key protein kinase 
involved in the DDR that is responsible for cell cycle check-
point activation and DNA repair following DNA damage 
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Figure 5 Vcr sensitizes gl261 cells to ir.
Notes: gl261 cells were exposed to 0.5–2 nM of Vcr in conjunction with 3–9 gy of ir. experiments with Vcr were performed in an identical fashion to those with MBZ. 
all data are expressed as the average ± seM of three independent experiments. For each radiation dose–response curve, data were normalized by the fraction of viable cells 
treated with a given dose of Vcr in the absence of ir. DeFs were determined at the point of 50% cell viability. (A) cells were treated with Vcr during 3–9 hours post ir. 
(B) cells were treated with Vcr for a 6-hour time window immediately prior to irradiation. (C) cells were treated with Vcr starting 6 hours prior to irradiation until 
72 hours post ir. (D–F) The respective DEFs were calculated as described in the “Cell viability assays” section. *P,0.05, **P,0.01, ***P,0.001.
Abbreviations: DEF, dose enhancement factor; IR, ionizing radiation; MBZ, mebendazole; SEM, standard error of the mean; VCR, vincristine.
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induced by IR.26 Nbs1 is a crucial component of an enzymatic 
complex that repairs double strand breaks (DSBs) following 
irradiation or heat shock.27
In control cells, which had not been treated with MBZ, 
Chk2 and Nbs1 were localized entirely in the nucleus 
(Figure 7A). Radiation treatment did not significantly alter 
the intracellular distribution of DDR proteins (Figure 7A). 
Treatment of glioma cells with MBZ sequestered Chk2 
and Nbs1 in the cytoplasm in a dose-dependent manner 
(Figure 7B and C). These results demonstrate that MBZ, like 
other MTAs,17 inhibits the trafficking of DDR proteins from 
the cytoplasm to the nucleus.
MBZ sensitizes glioma cells to ir by 
interfering with the trafficking of DDR 
proteins
To more closely examine the relationship between the effects 
of MBZ on intracellular trafficking of DDR proteins and IR 
sensitization, we compared the EC
50
 values for radiosensitiza-
tion (DEF), cytoplasmic sequestration of DDR proteins and 
induction of mitotic arrest by MBZ (Table 1) in GL261 cells. 
The EC
50
 was defined as the concentration of MBZ required 
to achieve a half-maximal effect. The EC
50
 of cytoplasmic 
sequestration for Chk2 (31 nM) and Nbs1 (25 nM) was 
significantly lower than the EC
50
 of mitotic arrest (192 nM). 
Most notably, the EC
50
 of radiosensitization (35 nM) was very 
similar to the EC
50
 for cytoplasmic sequestration of DDR 
proteins, but significantly lower than the EC
50
 of mitotic arrest 
(P,0.01). Similarly, the EC
50
 for radiosensitization by VCR 
(,0.5 nM) is significantly lower than the EC
50
 for mitotic 
arrest in GL261 cells (2.5 nM).23 These findings support the 
hypothesis that MBZ indeed radiosensitizes GL261 cells in 
large part by interfering with intracellular trafficking of DDR 
proteins during interphase.
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Figure 6 MBZ prolongs the DDr after exposure to ir.
Notes: (A) Western blot analysis. (B) Quantification of the Western blot bands. 
gl261 cells were treated with 6 gy of ir followed by treatment with 150 nM of 
MBZ during 3–9 hours post ir. control cells were treated only with ir. Following 
treatment, cell lysates were harvested at different time points (0.5–9 hours) post ir 
as described in the “Assessment of the DNA-damage response” section. Western 
blot analysis of γh2aX and h2aX levels was conducted at each time point post ir, 
and γh2aX levels were used as a measure of Dna damage. Data for each time point 
are expressed as the average ± seM of three independent experiments.
Abbreviations: DDR, DNA damage response; IR, ionizing radiation; MBZ, 
mebendazole; SEM, standard error of the mean.
Figure 7 MBZ interferes with the trafficking of DDR proteins from the cytoplasm to the nucleus.
Notes: (A) gl261 cell were exposed to ir for 9 hours or left untreated. cell lysates were collected using cytoplasmic and nuclear fractionation as described in the “nuclear 
and cytoplasmic fractionation” section. In untreated GL261 cells, DDR proteins are localized to the nucleus. Exposure to IR did not alter the intracellular distribution of 
DDr proteins. (B) gl261 cells were exposed to ir followed by application of 25–250 nM of MBZ during 3–9 hours post ir. Western blot analysis of the cytoplasmic and 
nuclear fractions was conducted, and the levels of DDR proteins, Chk2 and Nbs1, were quantified for each fraction. Exposure to MBZ post IR resulted in the dose-dependent 
sequestration of DDr proteins in the cytoplasm. (C) The histogram shows quantification of Chk2 and Nbs1 levels from three independent experiments ± se. *P,0.001.
Abbreviations: C, cytoplasmic; DDR, DNA damage response; IR, ionizing radiation; MBZ, mebendazole; N, nuclear; SE, standard error.
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radiosensitization by microtubule inhibitors
Discussion
Studying the mechanisms of action of MTAs in cell toxicity, 
and in particular whether MTAs target cells in mitotic 
phase or interphase, has been hampered by the difficulty in 
separating these two cell populations. In this study, we tran-
siently eliminated the mitotic cell population by irradiating 
glioblastoma cells, which allowed us to examine the extent 
to which the MTA, MBZ, can radiosensitize these cells in 
a cell population that is essentially made up of interphase 
cells only. Our results show that in this system, the effect 
of MBZ in interphase is responsible for the majority of the 
radiosensitization effect caused by this MTA.
For a long time, MTAs have been believed to inhibit 
tumor growth primarily by targeting mitotic cells, but this 
hypothesis has come under considerable scrutiny.11,12,15,16 
We examined the role of interphase microtubules by determin-
ing the effect of MBZ as a radiosensitizer, when present during 
a time window in which mitosis is prevented by G2–M cell 
cycle arrest. We showed that this regimen is better at radiosen-
sitization of tumor cells than when MBZ is present before IR 
administration, leading to an increase in the number of mitotic 
cells, and is very similar to that caused by chronic treatment 
with MBZ, strongly indicating that interphase microtubules are 
indeed the targets of MBZ. In addition, the EC
50
 of MBZ for 
radiosensitization is much lower than that for inducing mitotic 
arrest, further supporting the notion that the radiosensitizing 
effect of MBZ is independent of its effect on mitosis. We found 
essentially the same results for VCR. Thus, most likely this 
conclusion holds for a wide range of MTAs.
We also observed that MBZ, even when applied for only 
6 hours, leads to a strong delay in the DDR. Thus, our results 
strongly support the hypothesis that MTAs prolong DNA 
damage repair by interfering with the trafficking of DDR 
proteins from the cytosol to the nucleus.17
Interestingly, the EC
50
 for radiosensitization by MBZ 
(35 nM) is very similar to that of cytoplasmic sequestration 
of DDR proteins by MBZ (25 nM), which is much lower than 
the EC
50
 of MBZ for the induction of mitotic arrest (184 nM), 
further supporting the notion that MTAs radiosensitize by 
blocking trafficking of DDR proteins to the nucleus. The low 
EC
50
 of MBZ for the inhibition of DDR protein trafficking 
is surprising, because it is also much lower than the EC
50
 for 
microtubule depolymerization (132 nM) that we determined 
recently.23 This EC
50
 largely reflects that of the depolymer-
ization of interphase microtubules, as most of the cells are 
in interphase.
Although the mechanistic basis for the relatively low EC
50
 
of MBZ for the inhibition of DDR protein trafficking remains 
to be determined, it will be of great interest to examine 
whether our findings with MBZ extend to other MTAs. Our 
observation that radiosensitization can be accomplished at 
a concentration of MBZ that is significantly lower than the 
concentration needed for cell killing on its own also has 
important clinical implications, as it suggests the possibility 
to utilize a dose of MBZ that minimizes toxicity. Importantly, 
our results also have implications for the optimal timing 
of administration of MTAs when used as radiosensitizers. 
Indeed, we show that optimal radiosensitization is obtained 
when inhibition of microtubule formation is achieved during 
the post-IR DNA repair period.
This study also underlines the critical role of microtubule-
based transport in the response to DNA damage. Thus, further 
elucidation of these mechanisms may lead to the identifica-
tion of novel therapeutic targets for radiosensitization.
Conclusion
We have shown that MBZ sensitizes cancer cells to IR in 
a manner that is largely independent of the induction of 
mitotic arrest by this microtubule inhibitor. We also provide 
evidence that MBZ-induced radiosensitization is mediated by 
inhibiting DDR protein accumulation into the nucleus. Thus, 
this study strongly supports a critical role for DDR protein 
trafficking in the response to radiation, suggesting that ele-
ments of the protein trafficking machinery can be mined for 
additional radiosensitization targets.
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